Cancer biomarkers

Invasive Breast Cancer

(2017) Robert W. Carlson et al.   Journal of the National Comprehensive Cancer Network

Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force

(2013) Kenneth Lin et al.   ANNALS OF INTERNAL MEDICINE

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Comparison of Effect Sizes Associated With Biomarkers Reported in Highly Cited Individual Articles and in Subsequent Meta-analyses

(2011) John P. A. Ioannidis   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

(2011) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Biospecimen Reporting for Improved Study Quality (BRISQ)

(2011) Helen M. Moore et al.   JOURNAL OF PROTEOME RESEARCH

Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

(2010) Susan M. Domchek   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors

(2010) Timothy D. Gilligan et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Clinical Trials With Biomarkers: Design Issues

(2010) B. Freidlin et al.   JNCI-Journal of the National Cancer Institute

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

(2010) Gordon JS Rustin et al.   LANCET

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group

(2009) Steven M Teutsch et al.   GENETICS IN MEDICINE

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Sources of Bias in Specimens for Research About Molecular Markers for Cancer

(2009) David F. Ransohoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers

(2009) R. M. Simon et al.   JNCI-Journal of the National Cancer Institute

Commentary: Hormone Receptor Testing in Breast Cancer: A Distress Signal from Canada

(2008) D. C. Allred   ONCOLOGIST